High of the morning to you, and a effective one it’s. Clear blue skies and nice breezes are wafting throughout the Pharmalot campus, the place the official mascots are foraging for his or her breakfast and rousing the neighbors. This implies we’re free to give attention to the issues at hand — rummaging via our to-do record and making cups of stimulation. Our selection in the present day is lavender vanilla. Sounds appetizing, sure? As all the time, we invite you to hitch us. In the meantime, right here is the newest menu of tidbits that can assist you get began in your journey. We hope that your day is solely smashing and that you simply conquer the world. And naturally, do keep up a correspondence. We recognize options, criticism, and saucy ideas. …
The World Well being Group plans to formally again the usage of weight reduction medication to deal with weight problems in adults for the primary time, marking a shift in its strategy to treating the worldwide well being drawback, Reuters studies. The company additionally known as for methods to enhance entry to the therapy in low- and middle-income international locations. Greater than a billion folks now have weight problems worldwide, in accordance with the WHO, and round 70% of them stay in low- and middle-income international locations, the World Financial institution estimates. The WHO’s conditional advice shall be formally launched in August, as a part of new tips on treating weight problems. It is usually engaged on separate tips for youngsters and adolescents. Individually, WHO specialists can even meet subsequent week to resolve whether or not to incorporate the GLP-1 medication within the company’s important medicines record — each to deal with weight problems and kind 2 diabetes.
Novo Nordisk secured a significant win on insurance coverage protection of its weight problems drug, STAT notes. CVS Caremark, the biggest pharmacy profit supervisor within the U.S., introduced that beginning in July, Novo’s weight reduction therapy Wegovy would be the most popular GLP-1 drugs on its largest business formularies, doubtless making Wegovy extra accessible to sufferers than Zepbound, a rival drug from Eli Lilly. The weight problems market has been dominated by the 2 corporations, and in current months, traders had been viewing Lilly as having an edge, with Zepbound resulting in better weight reduction than Wegovy and with Lilly having what appears to be like to be extra promising injectable and oral candidates in its pipeline. However the CVS information is a big step for Novo, as each corporations have been attempting to broaden insurance coverage protection, a key hurdle for wider utilization.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
